vs
ICON PLC（ICLR）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
ICON PLC的季度营收约是Medpace Holdings, Inc.的2.9倍（$2.0B vs $708.5M）。Medpace Holdings, Inc.净利率更高（19.1% vs 0.1%，领先19.0%）。Medpace Holdings, Inc.同比增速更快（32.0% vs 0.6%）。ICON PLC自由现金流更多（$333.9M vs $188.1M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 0.6%）
ICON plc是总部位于爱尔兰的跨国医疗智能与临床研究服务机构，专注为全球医药健康领域客户提供专业研究及情报支持，截至2025年2月，已在全球55个国家布局业务，员工规模约4.19万人。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
ICLR vs MEDP — 直观对比
营收规模更大
ICLR
是对方的2.9倍
$708.5M
营收增速更快
MEDP
高出31.4%
0.6%
净利率更高
MEDP
高出19.0%
0.1%
自由现金流更多
ICLR
多$145.8M
$188.1M
两年增速更快
MEDP
近两年复合增速
0.6%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $708.5M |
| 净利润 | $2.4M | $135.1M |
| 毛利率 | — | — |
| 营业利润率 | 4.2% | 21.6% |
| 净利率 | 0.1% | 19.1% |
| 营收同比 | 0.6% | 32.0% |
| 净利润同比 | -98.8% | 15.5% |
| 每股收益（稀释后） | $0.03 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICLRMEDP
| Q4 25 | — | $708.5M | ||
| Q3 25 | $2.0B | $659.9M | ||
| Q2 25 | $2.0B | $603.3M | ||
| Q1 25 | $2.0B | $558.6M | ||
| Q4 24 | — | $536.6M | ||
| Q3 24 | $2.0B | $533.3M | ||
| Q2 24 | $2.1B | $528.1M | ||
| Q1 24 | $2.1B | $511.0M |
净利润ICLRMEDP
| Q4 25 | — | $135.1M | ||
| Q3 25 | $2.4M | $111.1M | ||
| Q2 25 | $183.0M | $90.3M | ||
| Q1 25 | $154.2M | $114.6M | ||
| Q4 24 | — | $117.0M | ||
| Q3 24 | $197.1M | $96.4M | ||
| Q2 24 | $146.9M | $88.4M | ||
| Q1 24 | $187.4M | $102.6M |
营业利润率ICLRMEDP
| Q4 25 | — | 21.6% | ||
| Q3 25 | 4.2% | 21.5% | ||
| Q2 25 | 10.4% | 20.9% | ||
| Q1 25 | 11.0% | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | 14.1% | 21.1% | ||
| Q2 24 | 10.8% | 19.9% | ||
| Q1 24 | 13.7% | 20.4% |
净利率ICLRMEDP
| Q4 25 | — | 19.1% | ||
| Q3 25 | 0.1% | 16.8% | ||
| Q2 25 | 9.1% | 15.0% | ||
| Q1 25 | 7.7% | 20.5% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | 9.7% | 18.1% | ||
| Q2 24 | 6.9% | 16.7% | ||
| Q1 24 | 9.0% | 20.1% |
每股收益（稀释后）ICLRMEDP
| Q4 25 | — | $4.65 | ||
| Q3 25 | $0.03 | $3.86 | ||
| Q2 25 | $2.30 | $3.10 | ||
| Q1 25 | $1.90 | $3.67 | ||
| Q4 24 | — | $3.67 | ||
| Q3 24 | $2.36 | $3.01 | ||
| Q2 24 | $1.76 | $2.75 | ||
| Q1 24 | $2.25 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $468.9M | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $459.1M |
| 总资产 | $16.5B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICLRMEDP
| Q4 25 | — | $497.0M | ||
| Q3 25 | $468.9M | $285.4M | ||
| Q2 25 | $390.4M | $46.3M | ||
| Q1 25 | $526.7M | $441.4M | ||
| Q4 24 | — | $669.4M | ||
| Q3 24 | $695.5M | $656.9M | ||
| Q2 24 | $506.6M | $510.9M | ||
| Q1 24 | $396.1M | $407.0M |
股东权益ICLRMEDP
| Q4 25 | — | $459.1M | ||
| Q3 25 | $9.3B | $293.6M | ||
| Q2 25 | $9.6B | $172.4M | ||
| Q1 25 | $9.5B | $593.6M | ||
| Q4 24 | — | $825.5M | ||
| Q3 24 | $9.8B | $881.4M | ||
| Q2 24 | $9.6B | $763.6M | ||
| Q1 24 | $9.4B | $671.5M |
总资产ICLRMEDP
| Q4 25 | — | $2.0B | ||
| Q3 25 | $16.5B | $1.8B | ||
| Q2 25 | $16.6B | $1.6B | ||
| Q1 25 | $16.7B | $1.9B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $17.2B | $2.1B | ||
| Q2 24 | $17.0B | $1.9B | ||
| Q1 24 | $17.0B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $387.6M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $333.9M | $188.1M |
| 自由现金流率自由现金流/营收 | 16.3% | 26.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.6% |
| 现金转化率经营现金流/净利润 | 164.59× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $681.9M |
8季度趋势，按日历期对齐
经营现金流ICLRMEDP
| Q4 25 | — | $192.7M | ||
| Q3 25 | $387.6M | $246.2M | ||
| Q2 25 | $146.2M | $148.5M | ||
| Q1 25 | $268.2M | $125.8M | ||
| Q4 24 | — | $190.7M | ||
| Q3 24 | $402.7M | $149.1M | ||
| Q2 24 | $218.6M | $116.4M | ||
| Q1 24 | $327.1M | $152.7M |
自由现金流ICLRMEDP
| Q4 25 | — | $188.1M | ||
| Q3 25 | $333.9M | $235.5M | ||
| Q2 25 | $113.9M | $142.4M | ||
| Q1 25 | $239.3M | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | $359.3M | $138.5M | ||
| Q2 24 | $182.3M | $103.5M | ||
| Q1 24 | $299.9M | $147.2M |
自由现金流率ICLRMEDP
| Q4 25 | — | 26.6% | ||
| Q3 25 | 16.3% | 35.7% | ||
| Q2 25 | 5.6% | 23.6% | ||
| Q1 25 | 12.0% | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | 17.7% | 26.0% | ||
| Q2 24 | 8.6% | 19.6% | ||
| Q1 24 | 14.3% | 28.8% |
资本支出强度ICLRMEDP
| Q4 25 | — | 0.6% | ||
| Q3 25 | 2.6% | 1.6% | ||
| Q2 25 | 1.6% | 1.0% | ||
| Q1 25 | 1.4% | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 2.1% | 2.0% | ||
| Q2 24 | 1.7% | 2.4% | ||
| Q1 24 | 1.3% | 1.1% |
现金转化率ICLRMEDP
| Q4 25 | — | 1.43× | ||
| Q3 25 | 164.59× | 2.22× | ||
| Q2 25 | 0.80× | 1.65× | ||
| Q1 25 | 1.74× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | 2.04× | 1.55× | ||
| Q2 24 | 1.49× | 1.32× | ||
| Q1 24 | 1.74× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICLR
| Other Customers | $681.3M | 33% |
| Clients1125 | $549.4M | 27% |
| Clients15 | $503.3M | 25% |
| Clients610 | $308.8M | 15% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
